Source : Perth Now news
Australia’s second-largest fertility services provider has suffered a drop in annual profit after a fall in the number of IVF treatment cycles started by patients.
But Monash IVF also said it’s picked up about one per cent more of the assisted reproduction market, giving it momentum running into the new financial year.
The group, which now has a market share of about 20 per cent, on Monday reported a 2025/26 bottom line net profit of $8.3 million, down 67.6 per cent from the previous year.
The result followed softer domestic stimulated cycle volumes, partially offset by growth in its international, genetics and ancillary revenue streams.
It also faced higher wages and supplier cost inflation, and clinic operating costs.
The underlying net profit was $16.1 million, below its recent guidance of a result between $17-$18 million, on revenue of $269.5 million.
But the second half of the year saw a pick-up in stimulated cycle volumes, as clinical pregnancy rates for women under 43 rose 1.8 per cent to 42.1 per cent over the year.
“Financial year 2026 was a year of two halves,” chief executive Victoria Atkinson said.
“While the first half was challenging, we exited the year with improved momentum, with domestic stimulated cycle volumes trends strengthening, market share increasing through the second half, and our international business delivering a record performance.”
Looking ahead, Dr Atkinson said the group was focused on growing cycle volumes and market share.
About 20,000 babies conceived by IVF are born in Australia each year, according to the latest figure from the Australian and New Zealand Assisted Reproduction database.
This represents about one in 18 children, rising to one in 10 for those born to mothers aged 35 and older.
In April, Monash IVF rejected a takeover offer of 90 cents per share from investment vehicle WHSP Holdings and private equity group Genesis Capital, saying that it undervalued the group.
It was not the first time the pair had cast their eyes over Monash IVF. They first pursued the target in November, when it was under pressure over an embryo implant scandal.
A patient at a laboratory in Melbourne’s southeast was implanted with her own embryo in June 2025 rather than one from her partner, as requested.
The company later blamed human error and IT limitations for the incident.
At the time, WHSP and Genesis offered 80 cents per share for all the stock in Monash IVF, which has struggled to trade above 90 cents for more than 12 months.
Its shares closed on Friday at 68 cents.
Monash IVF declared a final dividend of 1.3 cents, taking the total for the year to 2.5 cents.
